Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
March 05 2019 - 8:00AM
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage
company focused on the development and commercialization of novel
antibiotics to treat serious bacterial infections, today announced
it intends to release its fourth quarter and year-end 2018
financial results on March 13, 2019, after the close of the U.S.
financial markets.
Melinta will host a conference call and live
webcast on Wednesday, March 13, 2019 at 4:30 p.m.
ET to discuss its financial results and provide a business
update.
Conference Call and Webcast
On March 13, 2019 at 4:30 p.m. ET, the
live call may be accessed by dialing 877-377-7553 for domestic
callers and 253-237-1151 for international callers and using
conference ID #1698998. A live webcast of the call will be
available online from the investor relations section of the Melinta
website at www.melinta.com and will be archived there for
30 days.
A telephone replay of the call will be available
by dialing 855-859-2056 for domestic callers or 404-537-3406 for
international callers and entering the conference ID #1698998. The
webcast will be available from the Events & Presentations
section of Melinta’s Investor webpage.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest
pure-play antibiotics company, dedicated to saving lives threatened
by the global public health crisis of bacterial infections through
the development and commercialization of novel antibiotics that
provide new therapeutic solutions. Its four marketed products
include Baxdela® (delafloxacin), Vabomere® (meropenem and
vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline)
for Injection. This portfolio provides Melinta with the unique
ability to provide providers and patients with a range of solutions
that can meet the tremendous need for novel antibiotics treating
serious infections. Visit www.melinta.com for more information.
Forward Looking Statements
Certain statements in this communication
constitute “forward-looking statements” within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act and are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act and Section 21E of the Securities Exchange
Act and are making this statement for purposes of complying with
those safe harbor provisions. These forward-looking statements
reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made and include statements regarding: expectations with respect to
our financial position, results and performance. Although we
believe that our plans, intentions, expectations, strategies and
prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations, strategies or prospects will be attained
or achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control.
Risks and uncertainties for Melinta include, but
are not limited to, the fact that we have incurred significant
operating losses since inception and will incur continued losses
for the foreseeable future; our limited operating history; our need
for future capital and risks related to our ability to obtain
additional capital to fund future operations; risks related to the
satisfaction of the closing conditions for the remaining two
disbursements under the loan agreement with Vatera, including any
consequences of a failure to close on the two disbursements under
the Vatera loan financing; risks related to compliance with the
covenants under our facilities with Vatera and Deerfield;
uncertainties of cash flows and inability to meet working capital
needs as well as other milestones, royalty and payment obligations,
including as a result of the outcome of the pending litigation with
respect to, and any requirement to make, payments potentially due
to The Medicines Company; risks that may arise from the
consummation of the Vatera loan financing and the effectiveness of
the amendment to the Deerfield facility agreement, including
potential dilution to our stockholders and the fact that Vatera
will beneficially own a substantial portion of our common stock;
the fact that our independent registered public accounting firm’s
report on the Company’s 2016 and 2017 financial statements contains
(and that the report on the Company’s 2018 financial statements may
contain) an explanatory paragraph that states that our recurring
losses from operations and our need to obtain additional capital
raises substantial doubt about our ability to continue as a going
concern; our substantial indebtedness; risks related to the
commercial launches of our products and our inexperience as a
company in marketing drug products; the degree of market acceptance
of our products among physicians, patients, health care payors and
the medical community; the pricing we are able to achieve for our
products; failure to obtain and sustain an adequate level of
reimbursement for our products by third-party payors; inaccuracies
in our estimates of the market for and commercialization potential
of our products; failure to maintain optimal inventory levels to
meet commercial demand for any of our products; risks that our
competitors are able to develop and market products that are
preferred over our products; our dependence upon third parties for
the manufacture and supply of our marketed products; failure to
achieve the benefits of our recently completed transactions with
Cempra and The Medicines Company; failure to establish and maintain
development and commercialization collaborations; uncertainty in
the outcome or timing of clinical trials and/or receipt of
regulatory approvals for our product candidates; undesirable side
effects of our products; failure of third parties to conduct
clinical trials in accordance with their contractual obligations;
our ability to identify, develop, acquire or in-license products;
difficulties in managing the growth of our company; the effects of
recent comprehensive tax reform; risks related to failure to comply
with extensive laws and regulations; product liability risks
related to our products; failure to retain key personnel; inability
to obtain, maintain and enforce patents and other intellectual
property rights or the unexpected costs associated with such
enforcement or litigation; risks relating to third party
infringement of intellectual property rights; our ability to
maintain effective internal control over financial reporting;
unfavorable outcomes in any of the class action and shareholder
derivative lawsuits currently pending against the Company; and the
fact that a substantial number of shares of common stock may be
sold into the public markets by one or more of our large
stockholders in the near future. Many of these factors that will
determine actual results are beyond Melinta’s ability to control or
predict.
Other risks and uncertainties are more fully
described in our Annual Report on Form 10-K for the year ended
December 31, 2017, our Revised Definitive Proxy Statement filed
January 29, 2019, and in other filings that Melinta makes and will
make with the SEC. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. The statements made in this
press release speak only as of the date stated herein, and
subsequent events and developments may cause our expectations and
beliefs to change. While we may elect to update these
forward-looking statements publicly at some point in the future, we
specifically disclaim any obligation to do so, whether as a result
of new information, future events or otherwise, except as required
by law. These forward-looking statements should not be relied upon
as representing our views as of any date after the date stated
herein.
For More Information:
Media Inquiries:Lindsay RoccoElixir Health
Public Relations+1 862-596-1304lrocco@elixirhealthpr.com
Investor Inquiries:Susan BlumMelinta
Therapeutics(212) 355-4449ir@melinta.com
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Sep 2023 to Sep 2024